



## **Bio-Path Holdings Announces “At-the-Market” Offering with Cantor Fitzgerald**

**June 25, 2015; HOUSTON, TX** – Bio-Path Holdings, Inc., (NASDAQ: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it has established an “at-the-market” (“ATM”) program through which it may offer and sell up to \$25 million of common stock from time to time, at Bio-Path’s discretion, through Cantor Fitzgerald & Co., acting as sales agent. Sales of Bio-Path common stock under the ATM program may be made directly on or through the Nasdaq Capital Market, among other methods.

“This facility provides us with flexible access to capital at a time when Bio-Path’s product pipeline continues to make progress and we execute on our corporate strategy of maximizing our proprietary drug delivery technology to bring much needed oncology therapies to patients,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path. “We have not yet accessed the ATM facility and will be diligent in doing so. We continue to maintain financial discipline and currently intend to use this facility for specific product development initiatives, other working capital and general corporate purposes and largely only when market dynamics warrant.”

The offer and sale of shares of common stock under the ATM program will be made pursuant to a prospectus supplement to Bio-Path’s prospectus dated January 13, 2014, filed as part of the Company’s shelf registration statement on Form S-3 (file no. 333-192102), which was filed with, and declared effective by, the U.S. Securities Exchange Commission. The ATM offering may be made only by means of a prospectus supplement and the related prospectus.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Cantor Fitzgerald & Co. is the sales agent for the ATM offering. Copies of the prospectus supplement and the accompanying prospectus relating to these securities may be obtained by contacting Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59th Street, New York, New York 10022, telephone: 212-829-7122.

### **About Bio-Path Holdings, Inc.**

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase 2 study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.



*Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path's ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies and the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Bio-Path Holdings or at [www.sec.gov](http://www.sec.gov). Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

Contact Information:

Kara Andress  
Investor Relations  
Bio-Path Holdings, Inc.  
832-742-1357

Rhonda Chiger (investors)  
Rx Communications Group, LLC  
917-322-2569  
[rchiger@rxir.com](mailto:rchiger@rxir.com)